13Sep 2023
Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in T2D

Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in T2D

This study has characterized the pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes (T2D). The findings suggest that this innovative insulin regimen holds promise for managing T2D more effectively. The study involved 46 T2D patients who received subcutaneous once-weekly Icodec for over 8 weeks, with individualized doses aimed at maintaining target glucose levels. Model predictions showed that icodec's glucose-lowering effect was consistent throughout the dosing interval, with a duration of action lasting at least one week in all participants. Importantly, the trial found that once-weekly Icodec was well tolerated and safe.

  • #endo-diabetology

Like

Save

Share